45 citations
,
May 2024 in “International Journal of Molecular Sciences” This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.
April 2024 in “International journal of molecular sciences” This study examines the similarities and differences in the pathogenesis of autoimmune conditions alopecia areata and vitiligo, highlighting shared features like immune cell involvement and cytokine pathways, while noting differing immune responses in skin and hair.
1 citations
,
April 2024 in “Journal of Autoimmunity” This study found that rhIL-15 promotes human hair follicle growth and regrowth in experimental settings and may have therapeutic potential for alopecia areata by restoring immune privilege guardianship.
21 citations
,
January 2024 in “Science Immunology” This study developed a technique to limit genetic recombination to regulatory T cells to investigate whether self-tolerance is maintained in non-lymphoid tissues, an area previously not well understood.
4 citations
,
November 2023 in “Frontiers in immunology” In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.
23 citations
,
July 2023 in “Proceedings of the National Academy of Sciences” In this study using a mouse model and human data, researchers found that CD8+ T cells are central to driving alopecia areata, while regulatory T cells offer some protection, highlighting CD8+ T cells as key targets for future therapy development.
May 2023 in “Frontiers in Immunology” This article discusses the role of regulatory T cells in alopecia areata, where their deficiency in hair follicles may lead to impaired local immunity and suggests potential therapies like CAR-T reg cells and low-dose IL-2 to alleviate autoimmunity and promote hair regeneration in affected individuals.
7 citations
,
April 2023 in “Frontiers in immunology” This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.
30 citations
,
February 2023 in “Journal of Investigative Dermatology” OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
18 citations
,
February 2023 in “eLife” This study indicates that innate lymphoid cells-type 1 may provoke alopecia areata by disrupting hair follicle immune privilege and inducing characteristic lesions, challenging the view that alopecia areata is purely an autoantigen-dependent, T cell-driven condition.
1 citations
,
October 2022 in “International Journal of Molecular Sciences” This study suggests that allogenic human mesenchymal stem cell treatments have potential therapeutic effects by inducing immune tolerance and anti-inflammatory effects in severe alopecia areata patients.
13 citations
,
September 2022 in “Frontiers in immunology” This study found that Ifidancitinib, a JAK1/3 inhibitor, significantly promoted hair regrowth and reduced inflammation in a mouse model of alopecia areata by decreasing pathogenic T cell activity and inducing T cell exhaustion.
37 citations
,
August 2022 in “Frontiers in pharmacology” This study found that oral JAK inhibitors are effective and generally well-tolerated for treating alopecia areata, but high recurrence rates after stopping treatment suggest the need for continuous use.
5 citations
,
June 2022 in “Frontiers in immunology” This study observed that expanding regulatory T cells in the skin of mice with alopecia areata did not reverse the condition, indicating that additional immunotherapy may be necessary.
27 citations
,
August 2021 in “Journal of Autoimmunity” This study found that human dermal γδT-cells can act as stress sentinels and potentially trigger autoimmune responses toward stressed hair follicles, resembling features of alopecia areata.
23 citations
,
September 2020 in “Journal of Dermatological Science” This pilot study suggests that skin-resident γδT-cells may play a significant role in the early stages of alopecia areata pathogenesis, indicating a potential new target for therapeutic management.
22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” This review highlights the possible role of T regulatory cells in the immune-related mechanisms of alopecia areata but reports no new clinical findings.
134 citations
,
July 2020 in “Experimental dermatology” This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.
55 citations
,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This review discusses emerging research areas in alopecia areata pathobiology, highlighting the potential roles of unconventional immune cells and the need for more targeted therapeutic strategies, but reports no new experimental results.
5 citations
,
June 2019 in “British Journal of Dermatology” No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.
43 citations
,
February 2019 in “International immunology” This review examines the role of regulatory T cells in skin immune disorders, highlighting their unique functions in conditions like scleroderma, alopecia areata, and psoriasis, without reporting new clinical results.
56 citations
,
January 2019 in “Lancet” This review discusses the emerging use of JAK inhibitors in alopecia areata treatment and reports no new clinical results; it highlights hair regrowth despite symptom recurrence after stopping therapy.
16 citations
,
October 2018 in “Experimental Dermatology” This study suggests that mesenchymal stem cell therapy may improve cell viability and regulate key signaling pathways in vitro for treating alopecia areata.
46 citations
,
October 2018 in “JCI insight” In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.
27 citations
,
April 2018 in “Journal of autoimmunity” In this study, iNKT10 cells were found to play a significant role in preventing and treating alopecia areata in a humanized mouse model, suggesting these cells could have potential in managing related autoimmune disorders.
24 citations
,
March 2018 in “Experimental Dermatology” This review explores the role of regulatory T cells in autoimmune skin disorders like alopecia areata and vitiligo, emphasizing unanswered questions and reporting no new experimental results.
36 citations
,
April 2016 in “British journal of dermatology/British journal of dermatology, Supplement” This article reviews the role of vasoactive intestinal peptide in maintaining immune privilege in hair follicles and does not report new findings; the authors propose it as essential for immune homeostasis in alopecia areata.
82 citations
,
March 2016 in “Autoimmunity reviews” This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.
130 citations
,
August 2015 in “Experimental Dermatology” This review provides a comprehensive guide to serum-free human hair follicle organ culture methods, highlighting research opportunities, standardization efforts, and potential applications without reporting new empirical findings.
28 citations
,
March 2013 in “Journal of Investigative Dermatology” Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.
75 citations
,
October 2012 in “Journal of Investigative Dermatology” This study developed an animal model that recreates alopecia areata by injecting healthy human skin grafts in immunocompromised mice with peripheral blood mononuclear cells enriched for NKG2D+ and CD56+ cells.
421 citations
,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
717 citations
,
June 2010 in “Nature” This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.
132 citations
,
September 2009 in “Experimental Dermatology” This study introduced a new classification system for distinguishing between anagen VI and early catagen stages in human hair follicle organ culture, using it to confirm eflornithine's ability to induce premature catagen.
253 citations
,
December 2007 in “Journal of Investigative Dermatology” This study suggests that human hair follicles may actively suppress natural killer cells, which contrasts with the observed defects in NK cell regulation in alopecia areata.
92 citations
,
June 2005 in “Journal of Investigative Dermatology” This study found that the retinoid all-trans retinoic acid induced a catagen-like stage in human scalp hair follicles, suggesting upregulation of TGF-beta2 as a contributing mechanism.
190 citations
,
October 2002 in “The FASEB journal” In this study, androgen did not affect keratinocyte growth in coculture with androgenetic alopecia-derived dermal papilla cells, but did significantly suppress keratinocyte growth when androgen receptor was overexpressed in the papilla cells.
77 citations
,
June 2002 in “Journal of Investigative Dermatology” CD44 variant changes start alopecia areata, but don't maintain it.
133 citations
,
July 1994 in “Journal of Dermatological Science” In this study, the researchers developed an in vitro model that maintains human hair follicles to grow at in vivo rates and observed that factors like EGF and IGF-I influence hair follicle growth and catagen entry.